Haemodynamic effects of xenon or sevoflurane anesthesia on microcirculatio
Phase 1
- Conditions
- Patients with ASA III classification (left ventricular failure) undergoing implantation of a defibrillator.Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Registration Number
- EUCTR2013-004582-14-BE
- Lead Sponsor
- Department of Anesthesiology and Perioperative Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
patients with Left ventricular ejection fraction <30% undergoing the insertion of a defibrillator >18y-75y
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5
Exclusion Criteria
patients with ASA I and ASA II.
<18y
Normal LV function
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The aim of the study is the assessment of microcirculatory alterations induced by xenon or sevoflurane anesthesia in patients with compromised left ventricular systolic function.;Secondary Objective: Hemodynamic effects of xenon or sevoflurane anesthesia in patients with compromised left ventricular systolic function.;Primary end point(s): Microcirculatory changes induced by xenon or sevoflurane anesthesia.;Timepoint(s) of evaluation of this end point: Once the adequate anesthetic level (i.e. .6 of xenon or sevoflurane concentration measured by the anesthetic machine) is obtained with xenon or sevoflurane, microcirculation is assessed.<br>
- Secondary Outcome Measures
Name Time Method Secondary end point(s): N/A;Timepoint(s) of evaluation of this end point: N/A